Product Name: Meloxicam
CAS 71125-38-7
Appearance Light Yellow Powder
Purity 99%min
Standard EP/USP/BP
Samples Free
Synonyms: MOBIC;MOBEC;UH-AC 62XX;METACAM;MELOXICAM;Meiloxicam
MF: C14H13N3O4S2
MW: 351.4
Product Categories: Health & Beauty;Intermediates & Fine Chemicals;Pharmaceuticals
mp 255 °C
storage temp. 0-6°C
Stability: Stable. Incompatible with strong oxidizing agents.
Usage : Pharmaceutical intermediates.Preferential cyclooxygenase inhibitor. Sudoxicam and Meloxicam are nonsteroidal anti-inflammatory drugs from the enol-carboxamide class.
Specification:
| Item | Specification | Result |
| Appearance | yellowish powder | yellowish powder |
| Identification | A IR spectrum corresponds to the reference spectrum | Comform |
| heavy metals | ≤20ppm | Comform |
| Total impurities | ≤0.3% | 0.05% |
| Assay | 99.0%~101.0% | 99.8% |
| Conclusion: | conform to EP7.0 |
Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID).If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
Older patients and patients with an increased risk of adverse reactions;
In elderly patients, patients with rheumatoid arthritis and ankylosing spondylitis treatment recommended dose for
7.5mg/days. Starting dose in patients with increased risk of adverse reactions to 7.5mg/days.
Patients with renal insufficiency:
Patients with severe renal failure and need dialysis, the dose should not exceed 7.5mg/days.
Patients with mild to moderate renal insufficiency do not need to adjust the dosage (such as patients with creatinine
clearance greater than 25ml/minutes).
Patients with severe renal failure without dialysis.
Patients with hepatic insufficiency: In patients with mild and moderate hepatic insufficiency no need to adjust the
dose. In patients with severe hepatic insufficiency.
Children: This product is not for use in children under 15 years of age. Meloxicam has other forms, may apply.
Contact Methods:
Contact person: Rebecca Lee
Email: rebecca@tgybio.com/sales02@tgybio.com
What's up: +86 188 2921 5606 /+ 86 188 0296 2783
Skype: +86 188 2921 5606 /+ 86 188 0296 2783
China
